论文部分内容阅读
羟甲戊二酰辅酶 A 还原酶抑制剂(简称 HMG-CoARI)是一类降血脂新药,自1987年美国默克(Merck)公司研制的洛伐他定(Lovastatin 简称L)问世以来,普伐他定(Pravastatin 简称 P)、斯伐他定(Simvastatin 简称 S)相继问世,它们的上市是降血脂药研究进展中的一个里程碑,被认为是80年代医药产品的重大技术突破之一。1 HMG-CoARI 的作用机理人体胆固醇来源于体内的生化合成和从饮食中撮入,而以前者为主,它占人体胆固醇的70～80%,所以降低胆固醇的方法除了注意饮食外,更主要是抑制其在体内的生化合成。
HMG-CoARI is a class of hypolipidemic drugs. Since the advent of lovastatin (L) developed by the Merck Company in 1987, Pravastatin (P) and Simvastatin (S) have come out in succession. Their listing is a milestone in the progress of lipid-lowering drugs and is considered as one of the major technological breakthroughs in pharmaceutical products in the 1980s. 1 HMG-CoARI mechanism of action Human cholesterol comes from the body’s biochemical synthesis and from the diet to take into account, while the former mainly, it accounts for 70 to 80% of the body’s cholesterol, cholesterol lowering method in addition to pay attention to the diet, the more important Is to inhibit its biochemical synthesis in the body.